{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:43Z","timestamp":1787009443626,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antimicrobial stewardship programs can optimize antimicrobial use and have been federally mandated in all hospitals. However, best stewardship practices in immunocompromised patients with cancer are not well established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An antimicrobial time out, in the form of an email, was sent to physicians caring for hospitalized patients reaching 5 days of therapy for targeted antimicrobials (daptomycin, linezolid, tigecycline, vancomycin, imipenem\/cilastatin, meropenem) in a comprehensive cancer center. Physicians were to discontinue the antimicrobial if unnecessary or document a rationale for continuation. This is a quasi-experimental, interrupted time series analysis assessing antimicrobial use during the following times: period 1 (before time-out: January 2007-June 2010) and period 2 (after time-out: July 2010-March\/2015). The primary antimicrobial consumption metric was mean duration of therapy. Days of therapy per 1000 patient-days were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Implementation of the time-out was associated with a significant decrease in mean duration of therapy for the following antimicrobials; daptomycin: \u22120.89 days (95% confidence interval [CI], \u22121.38 to \u2212.41); linezolid: \u22120.89 days (95% CI, \u22121.27 to \u2212.52); meropenem: \u22120.97 days (95% CI, \u22121.39 to \u2212.56); tigecycline: \u22121.41 days (95% CI, \u22122.19 to \u2212.63); P &amp;lt; .001 for each comparison. Days of therapy\/1000 patient-days decreased significantly for meropenem (\u221243.49; 95% CI, \u221258.61 to \u221228.37; P &amp;lt; .001), tigecycline (\u221235.47; 95% CI, \u221244.94 to \u221226.00; P &amp;lt; .001), and daptomycin (\u22129.47; 95% CI, \u221215.25 to \u22123.68; P = .002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>A passive day 5 time-out was associated with reduction in targeted antibiotic use in a cancer center and could potentially be successfully adopted to several settings and electronic health records.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofae235","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T23:30:32Z","timestamp":1713915032000},"source":"Crossref","is-referenced-by-count":5,"title":["Implementation of an Automated Antibiotic Time-out at a Comprehensive Cancer Center"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7510-5470","authenticated-orcid":false,"given":"Frank P","family":"Tverdek","sequence":"first","affiliation":[{"name":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L","family":"Aitken","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"},{"name":"Center for Antimicrobial Resistance and Microbial Genomics, UTHealth McGovern Medical School , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E","family":"Mulanovich","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry S","family":"Cantu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"McDaneld","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F","family":"Chemaly","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"2024053113420633600_ofae235-B1","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024053113420633600_ofae235-B2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1086\/321880","article-title":"Impact of a hospital-based antimicrobial management program on clinical and economic outcomes","volume":"33","author":"Gross","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2024053113420633600_ofae235-B3","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1001\/jama.1988.03410240050030","article-title":"Imipenem overprescribing","volume":"260","author":"Taylor","year":"1988","journal-title":"JAMA"},{"issue":"Suppl 3","key":"2024053113420633600_ofae235-B4","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1093\/cid\/ciu566","article-title":"Demonstrating the value of antimicrobial stewardship programs to hospital administrators","volume":"59","author":"Nagel","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024053113420633600_ofae235-B5","first-page":"1","article-title":"Approved: new antimicrobial stewardship standard","volume":"36","author":"Joint Commission on Hospital A","year":"2016","journal-title":"Jt Comm Perspect"},{"key":"2024053113420633600_ofae235-B6","article-title":"Core Elements of Hospital Antibiotic Stewardship Programs","author":"Centers for Disease Control and Prevention"},{"key":"2024053113420633600_ofae235-B7","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1097\/CCM.0b013e318298291a","article-title":"A clinical trial comparing physician prompting with an unprompted automated electronic checklist to reduce empirical antibiotic utilization","volume":"41","author":"Weiss","year":"2013","journal-title":"Crit Care Med"},{"key":"2024053113420633600_ofae235-B8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/jac\/dkq018","article-title":"Reassessment of intravenous antibiotic therapy using a reminder or direct counselling","volume":"65","author":"Lesprit","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2024053113420633600_ofae235-B9","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamainternmed.2016.3646","article-title":"The new antibiotic mantra-\u201cshorter is better","volume":"176","author":"Spellberg","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2024053113420633600_ofae235-B10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/j.1875-9114.2012.01162.x","article-title":"Antimicrobial stewardship in patients with cancer","volume":"32","author":"Tverdek","year":"2012","journal-title":"Pharmacotherapy"},{"key":"2024053113420633600_ofae235-B11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/jhin.2002.1161","article-title":"Effectiveness of a multifaceted infection control policy in reducing vancomycin usage and vancomycin-resistant enterococci at a tertiary care cancer centre","volume":"51","author":"Shaikh","year":"2002","journal-title":"J Hosp Infect"},{"key":"2024053113420633600_ofae235-B12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/cncr.21115","article-title":"Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer","volume":"104","author":"Ohmagari","year":"2005","journal-title":"Cancer"},{"key":"2024053113420633600_ofae235-B13","author":"Chemaly"},{"issue":"10 Suppl","key":"2024053113420633600_ofae235-B14","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.7326\/M13-3016","article-title":"Antibiotic self-stewardship: trainee-led structured antibiotic time-outs to improve antimicrobial use","volume":"161","author":"Lee","year":"2014","journal-title":"Ann Intern Med"},{"key":"2024053113420633600_ofae235-B15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"2024053113420633600_ofae235-B16","author":"Centers for Disease Control and Prevention"},{"key":"2024053113420633600_ofae235-B17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024053113420633600_ofae235-B18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ajic.2007.07.002","article-title":"Recommended practices for surveillance: Association for Professionals in Infection Control and Epidemiology (APIC), Inc","volume":"35","author":"Lee","year":"2007","journal-title":"Am J Infect Control"},{"key":"2024053113420633600_ofae235-B19","doi-asserted-by":"crossref","first-page":"e4515","DOI":"10.1093\/cid\/ciaa1279","article-title":"Postprescription review with threat of infectious disease consultation and sustained reduction in meropenem use over four years","volume":"73","author":"Mani","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024053113420633600_ofae235-B20","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1128\/AAC.01348-12","article-title":"Impact of antibiotic use on carbapenem resistance in Pseudomonas aeruginosa: is there a role for antibiotic diversity?","volume":"57","author":"Pluss-Suard","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024053113420633600_ofae235-B21","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1128\/AAC.46.9.2920-2925.2002","article-title":"Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa","volume":"46","author":"Lepper","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2024053113420633600_ofae235-B22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1592\/phco.23.5.618.32197","article-title":"The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to beta-lactams in a large teaching hospital","volume":"23","author":"Regal","year":"2003","journal-title":"Pharmacotherapy"},{"key":"2024053113420633600_ofae235-B23","first-page":"1970","article-title":"National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011","volume":"173","author":"Dantes","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2024053113420633600_ofae235-B24","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1128\/AAC.00607-13","article-title":"Correlations of antibiotic use and carbapenem resistance in Enterobacterales","volume":"57","author":"McLaughlin","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024053113420633600_ofae235-B25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2016.04.022","article-title":"Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010\u20132014","volume":"85","author":"Lob","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024053113420633600_ofae235-B26","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024053113420633600_ofae235-B27","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1086\/342577","article-title":"Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection","volume":"35","author":"Quale","year":"2002","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae235\/57334749\/ofae235.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/5\/ofae235\/57978237\/ofae235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/5\/ofae235\/57978237\/ofae235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T17:49:39Z","timestamp":1717177779000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae235\/7658374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae235","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,4,25]]},"article-number":"ofae235"}}